You searched for: «sculptra»
Results 26 - 30 of 111
Page 6 of 23
  1. Media
  2. Newsroom

Galderma premieres positive interim results demonstrating the efficacy of its Injectable Aesthetics portfolio in addressing facial volume loss as a result of medication-driven weight loss

  • Three-month interim data from first-of-its-kind trial demonstrate that the combination of Sculptra® and Restylane® Lyft™ or Contour™ effectively improved the facial aesthetic appearance of patients experiencing medication-driven weight loss with associated facial volume loss1
  • A six-month extension study is ongoing to capture the combined
  1. Media
  2. Newsroom

AMWC 2024: Galderma to share new data from its leading injectable aesthetic portfolio

 

  1. Media
  2. Newsroom

Interim data from two ongoing investigator-initiated trials highlight the role of Sculptra® and Restylane® in addressing aesthetic changes associated with weight loss medications and menopause

  • New interim results from a six-month investigator-initiated trial (IIT) supported by Galderma, regarding the clinical sequencing of women in menopause, show the combination of Restylane Skinboosters™ and Sculptra drove meaningful improvements in skin barrier function, hydration and patient satisfaction, with the most pronounced gains in hydration – a critical factor for perimenopausal
  1. Media
  2. Newsroom

IMCAS 2024: Galderma to present latest updates from its unparalleled aesthetics portfolio reinforcing its leadership position

  • Galderma will share exciting phase III data on its novel, investigational, ready-to-use liquid botulinum toxin A, RelabotulinumtoxinA, further reinforcing its unprecedented efficacy and safety in treating frown lines and crow’s feet.1-3
  • Two symposia will educate on individualized treatment approaches by exploring the aesthetic lives of patien
  1. Media
  2. Newsroom

IMCAS 2025: Galderma’s broad presence and new data on recently launched products Restylane® SHAYPE™ and Relfydess® reaffirm its category leadership

  • Galderma will present new data on Relfydess (RelabotulinumtoxinA) – the first and only ready-to-use liquid neuromodulator created using PEARL™ Technology, which has now launched in multiple countries in Europe – including results from the phase IIIb RELAX trial, reinforcing its long-term efficacy and high patient satisfaction, as seen in the READY clinical trial program1-7
Results 26 - 30 of 111
Page 6 of 23